Zydus Biologics Faces Seven Observations Following USFDA Inspection of Ahmedabad Facility
Zydus Biologics’ Ahmedabad injectable facility gets 7 observations in USFDA inspection
The Economic Times
Image: The Economic Times
Zydus Lifesciences Ltd reported that the US Food and Drug Administration (USFDA) completed an inspection of its injectable plant in Ahmedabad, India, resulting in seven observations. The company plans to work closely with the USFDA to resolve these issues promptly.
- 01The USFDA conducted a Good Manufacturing Practice (GMP) inspection at Zydus Biologics' Ahmedabad facility.
- 02The inspection lasted from April 27 to May 5, 2026.
- 03Seven observations were noted, but none were related to data integrity.
- 04Zydus Lifesciences is committed to addressing the observations quickly.
- 05The company aims to maintain compliance with USFDA standards.
Advertisement
In-Article Ad
Zydus Lifesciences Ltd announced that the US Food and Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection of its injectable facility located at Zydus Biotech Park in Changodar, Ahmedabad, India. The inspection, which took place from April 27 to May 5, 2026, resulted in seven observations. Importantly, there were no observations related to data integrity, which is a critical aspect of compliance. Zydus Lifesciences stated that it will work closely with the USFDA to address these observations expeditiously, ensuring that the facility meets regulatory standards and maintains its operational integrity.
Advertisement
In-Article Ad
The observations may affect Zydus Biologics' ability to manufacture and distribute products in the US market if not resolved promptly.
Advertisement
In-Article Ad
Reader Poll
How concerned are you about regulatory inspections of pharmaceutical facilities?
Connecting to poll...
More about Zydus Lifesciences
Read the original article
Visit the source for the complete story.